AllSci News
Everest Medicines licenses Bejescin from Beijing Mabworks for Asia-Pacific commercialization
Everest Medicines (HKEX: 1952.HK) has secured exclusive rights to develop and commercialize Bejescin (MIL62, obinutuzumab beta injection) across the...
SOPHiA Genetics and Memorial Sloan Kettering form joint venture for precision oncology AI analytics
SOPHiA Genetics and Memorial Sloan Kettering move toward joint venture for precision oncology
Kexing's launches first-in-human testing for dual VEGF-Ang-2 BsAb in wAMD
China-based Kexing Biopharm has dosed the first subject in a Phase I clinical trial of GB10, a bispecific antibody targeting both VEGF and Angiopoietin-2...
Lilly's Korean siRNA parnter OliX raises USD 80m in PIPE funding
South Korea-based OliX Pharmaceuticals, Inc. (KOSDAQ: 226950) announced a private placement of newly issued common shares raising approximately KRW 110...
ADC Therapeutics' Zynlonta plus rituximab meets Phase III endpoint in DLBCL, but safety concerns emerge
Switzerland-based ADC Therapeutics SA (NYSE: ADCT) reported that loncastuximab tesirine-lpyl (Zynlonta) combined with rituximab met the primary endpoint of...
Regeneron expands CytomX collaboration to USD 4b for conditional bispecific cancer therapeutics
Regeneron's four-year-old collaboration with CytomX Therapeutics has been significantly expanded, with the companies announcing a broadened agreement that...
Alnylam Pharmaceuticals commits USD 2b to generative AI siRNA discovery collaboration with Inceptive
Alnylam Pharmaceuticals (Nasdaq: ALNY) has committed up to USD 2 billion to embed generative AI into its siRNA discovery engine, entering a strategic...
Innovent global first to seek approval for CLDN18.2 targeted ADC in China
China-based Innovent Biologics (HKEX: 01801) has submitted a New Drug Application (NDA) to China's National Medical Products Administration (NMPA) for...
DaltonTx launches agentic AI drug discovery platform with Sygnature Discovery collaboration
UK-based DaltonTx has launched its Dalton drug discovery platform and announced Sygnature Discovery as its first named CRO client, marking the public...
Mineralys repurchases Tanabe royalties on lorundrostat for USD 200m
Mineralys Therapeutics (Nasdaq: MLYS) has agreed to pay Tanabe Pharma Corporation USD 200 million upfront to extinguish all future royalty obligations on...
Verastem Oncology’s KRAS G12D inhibitor earns FDA Fast Track for non-small cell lung cancer
Boston-based Verastem Oncology (Nasdaq: VSTM) announced receipt of US FDA Fast Track Designation for VS-7375, an oral selective KRAS G12D (ON/OFF) inhibitor,…
Spanish ADC firm Ona Therapeutics closes Series B round at USD 86.6m
Spain-based Ona Therapeutics has closed an oversubscribed USD 86.6 million Series B financing round to advance its antibody-drug conjugate (ADC) pipeline...
Terremoto Bio’s AKT1 inhibitor receives FDA Fast Track status for breast cancer
South San Francisco-based Terremoto Biosciences unveiled the receipt of US FDA Fast Track Designation for TER-2013, an orally bioavailable, AKT1-selective small molecule…
Juncell Therapeutics' nolgileucel meets primary endpoint in Phase II advanced melanoma trial
China-based Juncell Therapeutics reported that nolgileucel (GC101), its autologous tumor-infiltrating lymphocyte therapy, met the primary endpoint in a...
Jade Bio raises USD 150m via public offering to accelerate autoimmune antibody pipeline
San Francisco-based Jade Biosciences, Inc. (Nasdaq: JBIO) announced the pricing of a public offering of common stock to raise USD 150 million in gross...
The AllSci Brief
Free, systematic R&D and deal news. Daily.